SecBot SecBot
DEFA14A ·Filed Nov 10, 2026

HSCS

HeartSciences Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed7d 8h ago SEC0001213900-26-117805
Proxy solicitation materials
Actionable Insight • Neutral

Monitor the shareholder vote on the merger; DCG's 94.1% voting power post-merger means the combined company will be controlled by a single crypto-focused parent. The reverse acquisition structure and reliance on Nasdaq controlled-company exemptions are key governance features to watch.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$2.40
T+0 close · Nov 10, 2026 · via day close
Latest settled
−13.99%
T+5 · $2.06
Vs SPY
−11.66%
α at T+5
Next horizon
T+20
in 22d
  1. T+0 · Nov 10 $2.40entry
  2. T+1 · 6d ago −4.18%α −5.49% · $2.30
  3. T+5 · 11h ago −13.99%α −11.66% · $2.06
  4. T+20 · in 22d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

HeartSciences filed a DEFA14A supplementing its definitive proxy statement for the all-stock merger with Fortitude Mining Holdings, a Zcash-focused crypto miner. The supplement names the nine-member combined company board (seven DCG designees plus two current HeartSciences directors), discloses employment agreements for the incoming CFO ($425K base) and CHRO ($300K base), and updates the pro forma purchase price estimate to $26.1 million. The filing is routine proxy solicitation material ahead of the shareholder vote.

Key Financial Metrics

Vote
merger approval

Key Facts

  • Combined company board set at nine members: two from HeartSciences (Simpson, Wells) and seven DCG designees (Higgins, Koster, Leverton, Shifke, Stitzel, Wurtzel, Yacavone).
  • Jaime Leverton to be CEO, Mark Shifke to be Chair, Simcha Wurtzel to be Lead Independent Director.
  • Erik Ellingson (CFO) employment agreement: $425K base salary, 100% target bonus, option for 0.75% of combined company shares.
  • Stephanie Marchioni (CHRO) employment agreement: $300K base salary, 50% target bonus, $150K in RSUs.
  • Pro forma purchase price estimated at $26.1 million (equity consideration $20.7M plus $5.4M for pre-combination services on HeartSciences equity awards).
  • DCG will hold 94.1% of total voting power post-merger (100% of Class V common, 11.43% of Class A common).
  • Combined company will rely on controlled company exemptions from Nasdaq governance rules.
  • Three independent directors expected: Higgins, Wells, Wurtzel.

Financial Impact

Estimated purchase consideration of $26.1 million (equity consideration $20.7M plus $5.4M for pre-combination services).

ownership structurevoting control

Risk Factors

  • Merger may not close if HeartSciences shareholders do not approve the transaction.
  • Post-merger, the combined company will be controlled by DCG (94.1% voting power), reducing minority shareholder influence.
  • The company will rely on controlled company exemptions from Nasdaq governance requirements, limiting independent board oversight.
  • Fortitude's business is tied to Zcash mining and digital asset prices, which are highly volatile.

Market Snapshot

Exchange
Nasdaq
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001213900-26-117805
Document: 0001213900-26-117805-index-headers.html0001213900-26-117805
Document: 0001213900-26-117805-index.html0001213900-26-117805
Document: 0001213900-26-117805.txt0001213900-26-117805

Track record

73 reports on HSCS

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +92.83% at T+20 after the Aug 20, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 17, 2026today S-3/A Bearish 5/10 Entry $2.13 Now $2.06 +3.29% settles Nov 19
  2. Nov 17, 2026today DEFA14A Neutral 5/10 Entry $2.13 Now $2.06 −3.29% settles Nov 18
  3. Nov 13, 20264d ago DEFA14A Neutral 5/10 Entry $2.08 to $2.06 Now $2.06 −0.96% ▼ −0.96% +0.05% vs SPY
  4. Nov 13, 20264d ago DEFA14A Neutral 4/10 Entry $2.13 to $2.08 Now $2.06 −3.06% ▼ −2.12% −0.21% vs SPY
  5. Nov 13, 20264d ago 8-K/A Bearish 5/10 Entry $2.13 to $2.08 Now $2.06 +3.06% ▲ +2.12% +0.21% vs SPY
  6. Nov 12, 20265d ago DEFA14A Neutral 4/10 Entry $2.26 to $2.13 Now $2.06 −8.85% ▼ −5.97% −5.61% vs SPY
  7. Nov 10, 20267d ago DEFA14A Neutral 4/10 Entry $2.30 to $2.26 Now $2.06 −10.24% ▼ −1.53% −1.17% vs SPY
  8. Nov 10, 20267d ago DEFA14A Neutral 4/10 Viewing Entry $2.40 to $2.30 Now $2.06 −13.99% ▼ −4.18% −5.49% vs SPY
  9. Nov 10, 20267d ago DEFA14A Neutral 3/10 Entry $2.40 to $2.30 Now $2.06 −13.99% ▼ −4.18% −5.49% vs SPY
  10. Nov 9, 20268d ago DEFA14A Neutral 4/10 Entry $2.40 to $2.30 Now $2.06 −13.99% ▼ −4.18% −5.49% vs SPY
Showing 10 of 73

US Market Status

Market Closed · Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026